abiraterone,olaparib
clovis oncology,merck,gsk,pfizer,astrazeneca
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'propel', 'gsk', '$gsk', '$pfe', '$mrk', '$clvs', '$azn']
$azn $mrk #gu23 late-breaker on propel os analysis is out. key detail will be os result in non-hrr population, which i can't find in nejm, and which is likely negative (nb 3mth pdufa delay). here's how pfs is playing out $gsk $clvs $pfe 
Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.